<DOC>
	<DOCNO>NCT01027351</DOCNO>
	<brief_summary>The propose study V72P6E1 Extension Study V72P6 ( NCT00381615 ) . The objective extension study explore antibody persistence approximately 40 month age evaluate safety , tolerability immunogenicity booster dose rMenB±OMV NZ administer subject approximately 40 month age . Antibody persistence subsequently measure 18-20 month booster dose subject 60 month age . Two group naïve subject , age approximately 40 60 month , recruit study serve baseline comparator assess antibody persistence age . These subject receive two-dose catch-up regimen rMenB+OMV NZ . Subjects enrol 40 month age offer DTaP/IPV MMR vaccination , already receive vaccine prior enrollment .</brief_summary>
	<brief_title>Extension Study Evaluating Antibody Persistence Safety , Tolerability Immunogenicity Booster Doses Novartis rMenB±OMV NZ Vaccine Healthy UK Children Who Previously Received One Four Doses Same Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Healthy 40 44monthsold child , participate complete study V72P6 ( NCT00381615 ; followon subject ) Healthy 40 44months 60 62monthsold child ( naïve subject ) Previous ascertain suspected disease cause N. meningitidis History severe allergic reaction previous vaccination hypersensitivity vaccine component Any serious chronic progressive disease Known suspect impairment/alteration immune system Receipt , intent immunize another vaccine , within 30 day prior vaccination investigational vaccine ( within 14 day license flu vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>40 Months</minimum_age>
	<maximum_age>62 Months</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Children</keyword>
	<keyword>Pre-school</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Prevention</keyword>
	<keyword>Vaccination</keyword>
</DOC>